Citizens lowered the firm’s price target on Spruce Biosciences (SPRB) to $170 from $180 and keeps an Outperform rating on the shares. The firm continues to like Tralesinidase Alfa Enzyme Replacement Therapy’s opportunity in Sanfilippo Syndrome Type B and views the path to approval as relatively derisked in the ultra-rare disease, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences Updates ATM Agreement, Strengthens Leadership Team
- Spruce Biosciences appoints Dale Hooks as chief commercial officer
- Biotech Alert: Searches spiking for these stocks today
- Regulatory De-Risking and Extended Runway Underpin Maintained Buy Rating on Spruce Biosciences
- Spruce Biosciences price target lowered to $200 from $220 at H.C. Wainwright